Xintela’s oncology subsidiary, Targinta AB, and MSK’s Therapeutics Accelerator to develop integrin α10β1 antibody therapeutic in patients with aggressive sarcoma
Evy Lundgren-Åkerlund, CEO Xintela and Targinta, said, “The collaboration with MSK gives us a fantastic opportunity to clinically develop Targinta’s antibodies, targeting integrin α10β1, together with a leading global cancer center. In preclinical cancer models, we have shown that our lead candidates TARG9, an ADC (Antibody-drug conjugate), and TARG10, a function-blocking antibody, effectively inhibit tumor growth and metastasis of aggressive cancers such as triple-negative breast cancer, glioblastoma and sarcoma. Published results from Dr. Samuel Singer’s research group at MSK (Okada et al, 2016) complement our results and further validate integrin α10β1 as a unique cancer target. This collaboration will now create the opportunity to bring Targinta’s new targeted cancer therapy to patients for the first time. This is a breakthrough for Xintela’s oncology program and a great milestone for our wholly owned subsidiary Targinta.
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data